Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
Cardiol Therapeutics Inc. reports clinical, financing, and corporate updates as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead oral small-molecule candidate, CardiolRx, modulates inflammasome pathway activation associated with inflammation and fibrosis in pericarditis, myocarditis, and heart failure.
Recurring developments include the MAVERIC program in recurrent pericarditis, the completed ARCHER Phase II study in acute myocarditis, peer-reviewed publication of clinical data, U.S. trial-network updates, intellectual-property disclosures, and development of CRD-38 for heart failure and other inflammatory heart diseases. Company news also covers bought deal financings, common share and warrant offerings, annual operating updates, and healthcare conference presentations.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference at the InterContinental Boston Hotel on August 11, 2026, at 9:00 a.m. EDT. A live webcast will be available via the Investors “Events & Presentations” section on the company’s website.
Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Lead candidate CardiolRx™ is being evaluated in the Phase III MAVERIC trial for recurrent pericarditis and has Orphan Drug Designation from the U.S. FDA. The completed Phase II ARCHER study assessed CardiolRx™ in acute myocarditis. Cardiol is also developing CRD-38, a subcutaneous formulation targeting inflammatory heart disease, including heart failure.
Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) announced that results from its Phase II MAvERIC study of CardiolRx™ in recurrent pericarditis have been published in the peer-reviewed Journal of the American Heart Association. The study found CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with high baseline disease burden, substantial decreases in pericarditis episodes per year, and a favorable safety and tolerability profile.
According to Cardiol, these Phase II findings provided the clinical rationale for MAVERIC, a randomized, double-blind, placebo-controlled pivotal Phase III trial evaluating CardiolRx™ for reducing the risk of pericarditis recurrence. Enrollment in MAVERIC is now approaching completion, supported by strong patient interest and highlighting the unmet need in recurrent pericarditis.
Cardiol Therapeutics (NASDAQ: CRDL), a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will join a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026 at 12:20 p.m. EDT.
The event takes place at the InterContinental Boston Hotel, Abigail Adams Salon B.
Cardiol Therapeutics (NASDAQ: CRDL, TSX: CRDL) reported voting results from its Annual General Meeting held virtually on June 24, 2026. Shareholders approved all management resolutions, including the election of eight directors and the appointment of BDO Canada LLP as auditor for the next fiscal year.
Cardiol Therapeutics (NASDAQ:CRDL) will webcast its virtual Annual General Meeting of Shareholders on June 24, 2026, at 4:30 p.m. EDT.
The AGM will be held as a live webcast only, with participation and voting details available on the company’s investor events webpage.
Cardiol Therapeutics (NASDAQ:CRDL) will participate in a Fireside Chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ in New York.
The session is scheduled for May 19, 2026 at 1:30 p.m. EDT, with a live webcast and a replay available for 90 days.
Cardiol Therapeutics (NASDAQ: CRDL) announced Phase II MAvERIC results have been accepted for publication in the Journal of the American Heart Association.
The peer-reviewed report links CardiolRx treatment to rapid, sustained reductions in pericarditis pain and inflammation, a substantial reduction in yearly pericarditis episodes, a favorable safety profile, and supports the ongoing pivotal Phase III MAVERIC trial, which has surpassed 75% enrollment.
Cardiol Therapeutics (NASDAQ: CRDL) announced expansion of its pivotal Phase III MAVERIC trial in the U.S., planning up to seven additional clinical centers to reach an anticipated total of 25 sites.
Patient enrollment has reached 75%, with target recruitment expected by end of Q2 2026 but potentially extending into Q3 2026. MAVERIC is a randomized, placebo-controlled trial of CardiolRx™ designed with FDA alignment and intended to support a future NDA.
Cardiol Therapeutics (NASDAQ: CRDL) announced a live interview with Barchart on X today, April 14, 2026, at 12:00 PM EDT featuring CEO David Elsley. Topics include the pivotal Phase III MAVERIC trial for recurrent pericarditis, published Phase II ARCHER myocarditis results, and next-gen drug CRD-38.
Investors can join live at x.com/Barchart; a full recording will be posted on Cardiol's X channel (@CardiolRx) and Barchart's channel after the event.
Cardiol Therapeutics (NASDAQ: CRDL) reported year-end 2025 operational progress: initiated pivotal Phase III MAVERIC in recurrent pericarditis (>50% enrolled; full enrollment expected Q2 2026), reported positive Phase II ARCHER results (LV mass reduction of -9.2g, p=0.0117), advanced CRD-38 toward IND/Phase I, received a U.S. patent allowance through Oct 2040, strengthened its board, and raised $31M in financings, funding operations into Q4 2027.
Key priorities include completing MAVERIC enrollment, initiating CRD-38 clinical work, and pursuing strategic partnerships.